FNDC5 and irritable bowel syndrome: In an experimental rodent model of mild IBD, treatment with exogenous irisin decreased the inflammatory markers during IBD, ameliorating changes in the colon, gut lymphatic structure, and bone tissue by reducing TNF-α and protein expression of RANKL [45].